Viking touts once-a-month weight loss maintenance data

Data ReadoutpositivePositive

AI Analysis

Summary

Viking Therapeutics announced positive data showing that patients switching to a once-a-month dosing regimen of its obesity drug experienced minimal weight regain over 12 weeks, supporting the viability of less frequent dosing schedules.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Patients on once-a-month dosing regimen showed minimal weight regain after 12 weeks

Importance:6/10

Sentiment:

0.70

obesityweight lossdosing regimenmaintenance therapy

Related Companies

$VKTX

Read the original article

Published by Endpoints News on September 22, 2026 3:07 PM

Read Original